UBS analyst Eliana Merle raised the firm’s price target on PTC Therapeutics (PTCT) to $80 from $71 and keeps a Buy rating on the shares. The FDA approved Sephience for the treatment of phenylketonuria in adults and children aged 1 month old and older, and and while this was expected, it is still a major de-risking event, the analyst tells investors in a research note. UBS sees PKU as a major opportunity for PTC and sees the potential for a strong U.S. launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Positive Outlook for PTC Therapeutics’ Sephience: Strong Market Potential and Revenue Prospects
- PTC Therapeutics price target raised to $46 from $42 at Barclays
- PTC Therapeutics Gains FDA Approval for Sephience
- PTC Therapeutics trading resumes
- PTC Therapeutics announces FDA approval of Sephience for treatment of PKU